This is a summary, written by members of the CITF Secretariat, of: Vinh DC, Gouin JP, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, Sengupta A, Brassard JP, Guerra A, Dziarmaga R, Perez A, Sun Y, Li Y, Roussel L, Langelier J, Ke D, Arnoldd C, Pelchat M, Langlois MA, Zhang X, Mazer BD. Real-world [...]
In this study, led by CITF-funded researchers Drs. Andrew Costa and Dawn Bowdish at McMaster University and published in JAMDA, people in retirement and nursing homes were sampled to measure antibody mediated immunity after the second and third doses of mRNA SARS-CoV-2 vaccines.
While two doses of COVID-19 vaccine can prevent serious illness in most cases, vaccine-induced immune responses decline naturally over time, which leads to an increased risk of breakthrough infections.
In a pre-print, not yet peer reviewed, study led by CITF-funded researchers Drs. Andrew Costa and Dawn Bowdish at McMaster University, people in retirement or nursing homes had repeat blood samples taken to measure immunity after the second and third doses of SARS-COV-2 mRNA vaccines.
Findings from a CITF-funded study led by Drs. Andrew Costa and Dawn Bowdish at McMaster University helped inform the federal government’s decision to recommend a third dose of COVID-19 vaccine for long-term care residents.
Findings from a real-world vaccination study composed of seniors residing in long-term care facilities were recently released in preprint, therefore not yet peer-reviewed, on behalf of investigators from the CITF-funded study UNCoVER (including Dr. Donald Vinh, Research Institute of the McGill University Health Centre (RI-MUHC) and Dr. Marc-André Langlois, University of Ottawa) and the CITF Secretariat (Dr. Bruce Mazer, Associate Director, Strategy, affiliated with the MUHC).
In a recent CITF-funded study, not yet peer-reviewed, researchers from McMaster University Dr. Andrew Costa and Dr. Dawn Bowdish, in collaboration with the COVID in Long Term Care Study Group, examined immunity responses to COVID-19 vaccines in nursing home residents after two doses of Moderna or Pfizer-BioNTech vaccines.
Published recently in BMJ Open, researchers Drs. Xiao-Li Pang, Bonita Lee and Christopher Sikora outline their CITF-funded study protocol for monitoring COVID-19 immunity using two very different channels: sewage and blood.
This CITF-funded research, which is in pre-print, was led by Lunenfeld-Tanenbaum Research Institute (LTRI) senior scientists Dr. Anne-Claude Gingras and Dr. Allison McGeer and reveals that long-term care (LTC) residents in Ontario who received the Pfizer vaccine had lower antibody responses to Alpha, Beta and Gamma than those vaccinated with the Moderna vaccine. The Delta variant was not assessed.
Long-term care residents and staff immunized with the Moderna vaccine elicited stronger total and neutralizing antibody responses compared to those vaccinated with Pfizer-BioNTech, according to new research.